Modulation of metal-azolate frameworks for the tunable release of encapsulated glycosaminoglycans†
| Autor: | Patricia Horcajada, Christian J. Doonan, Arpita Poddar, Paolo Falcaro, Pablo Salcedo-Abraira, Miriam de J. Velásquez-Hernández, Heinz Amenitsch, John E. Paderi, Helmar Wiltsche, Glenn D. Prestwich, Weibin Liang, Sarah Winkler, Efwita Astria, Ravi Shukla |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
biology
fungi 02 engineering and technology General Chemistry Heparin 010402 general chemistry 021001 nanoscience & nanotechnology 01 natural sciences Dermatan sulfate Heparin lyase 0104 chemical sciences 3. Good health Glycosaminoglycan chemistry.chemical_compound Chemistry chemistry Proteoglycan Drug delivery Hyaluronic acid biology.protein medicine Biophysics Chondroitin sulfate 0210 nano-technology medicine.drug |
| Zdroj: | Chemical Science |
| ISSN: | 2041-6539 2041-6520 |
| Popis: | Glycosaminoglycans (GAGs) are biomacromolecules necessary for the regulation of different biological functions. In medicine, GAGs are important commercial therapeutics widely used for the treatment of thrombosis, inflammation, osteoarthritis and wound healing. However, protocols for the encapsulation of GAGs in MOFs carriers are not yet available. Here, we successfully encapsulated GAG-based clinical drugs (heparin, hyaluronic acid, chondroitin sulfate, dermatan sulfate) and two new biotherapeutics in preclinical stage (GM-1111 and HepSYL proteoglycan) in three different pH-responsive metal-azolate frameworks (ZIF-8, ZIF-90, and MAF-7). The resultant GAG@MOF biocomposites present significant differences in terms of crystallinity, particle size, and spatial distribution of the cargo, which influences the drug-release kinetics upon applying an acidic stimulus. For a selected system, heparin@MOF, the released therapeutic retained its antithrombotic activity while the MOF shell effectively protects the drug from heparin lyase. By using different MOF shells, the present approach enables the preparation of GAG-based biocomposites with tunable properties such as encapsulation efficiency, protection and release. Clinical and pre-clinical GAG-based biotherapeutics were encapsulated within three metal-azolate frameworks (ZIF-8, ZIF-90, and MAF-7). The resulting MOF biocomposites show different loading capacity, biopreservation properties and release profiles. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|